Las Vegas Jury Handed Latest U.S. Case Over Takeda's Actos Risks
This article was originally published in PharmAsia News
Executive Summary
In the latest trial to go to a jury, Takeda Pharmaceutical denied in closing arguments that it hid bladder-cancer risks from patients who took its Actos (pioglitaizone) to treat their diabetes.